Therapies that restore PPAR-γ signaling, either by using direct PPAR-γ agonists or by inhibiting ET-1 activity, may have a potential role in the treatment of PPHN, while a combination of PPAR-γ agonists and bosentan may be useful. The gene discussed is PPARG; the disease is persistent fetal circulation syndrome.